MANGOCEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $456,021 | $615,873 | $731,493 | $8,939 | — |
| Cost of revenue | $54,422 | $93,296 | $154,900 | $4,089 | — |
| Gross profit | $250,386 | $379,964 | $431,501 | $4,850 | — |
| Operating expenses | $18.3M | $8.4M | $9.7M | $2.0M | — |
| Operating income | -$18.0M | -$8.0M | -$9.2M | -$2.0M | — |
| Interest expense | $103,513 | $13,700 | $6,473 | $6,473 | — |
| Pretax income | -$20.6M | -$8.7M | -$9.2M | -$2.0M | — |
| Net income | -$20.6M | -$8.7M | -$9.2M | -$2.0M | — |
| Balance Sheet | |||||
| Cash and equivalents | $1.5M | $58,653 | $739,006 | $682,860 | — |
| Current assets | $1.5M | $75,595 | $835,402 | $694,605 | — |
| Total assets | $16.1M | $15.4M | $1.1M | $1.0M | — |
| Current liabilities | $890,568 | $1.4M | $211,078 | $260,577 | — |
| Total liabilities | $890,568 | $1.4M | $276,039 | $389,257 | — |
| Stockholders' equity | $15.2M | $13.9M | $774,754 | $614,030 | -$16,720 |
| Cash Flow Statement | |||||
| Cash from operations | -$5.9M | -$4.9M | -$7.0M | -$1.3M | — |
| Depreciation and amortization | $1,012 | $9,936 | $24,889 | $3,863 | — |
| Stock-based compensation | $1.2M | $248,682 | $624,463 | $234,088 | — |
| Capital expenditure | — | — | $3,519 | $43,102 | — |
| Free cash flow | — | — | -$7.0M | -$1.4M | — |
| Impairments | — | $0 | $0 | — | — |
Shares outstanding 17.2M · Free float 76.4%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.